CXCR4 and pancreatic neoplasm: The CXCR4 antagonist motixafortide (BL-8040), which can inhibit the immunosuppressive CXCL12-CXCR4 axis driven by FAP + CAFs, is currently being investigated in phase II clinical trials involving pancreatic cancer patients in combination with pembrolizumab and/or chemotherapy (NCT02826486).